Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
absorption, attended, capped, flat, milestone, newly, preliminarily, preliminary, scenario, sequential, slight, submitted, wear
Removed:
ePatch, minimal, month
Financial report summary
?Risks
- Reimbursement by Medicare is highly regulated, and subject to change and our failure to comply with applicable regulations could decrease our revenue, subject us to penalties or adversely affect our results of operations.
- Changes in the reimbursement rate that commercial payors and Medicare will pay for our products and services could adversely affect our operating performance.
- Our revenues could be affected by third-party reimbursement policies and potential cost constraints.
- Billing for our products and service is complex, and we must dedicate substantial time and resources to the billing process.
- Failure to appropriately track and report certain payments to physicians and teaching hospitals may violate certain federal reporting laws and subject us to fines and penalties.
- Audits or denials of our claims by government agencies and commercial payors could reduce our revenue and have an adverse effect on our results of operations.
- We have a concentrated number of payors and losing one of them would reduce our sales and adversely affect our business and operating results.
- If we are unable to provide service in a timely manner, physicians may elect not to prescribe our services, and our revenue and growth prospects may be adversely affected.
- Cost-containment efforts of group purchasing organizations could adversely affect our selling prices, financial position and results of operations.
- We are increasingly dependent on sophisticated information technology systems to operate our business, and if we fail to properly maintain the integrity of our data or if our products do not operate as intended or we experience a cyber-attack or other breach of these systems, our business could be materially affected.
- Violation of federal and state laws regarding privacy and security of patient information or other personal information may adversely affect our business, financial condition or operations.
- Resolution of income tax matters may impact our financial condition, results of operations and cash flows.
- Our business is subject to the risks of international operations.
- If we do not obtain and maintain adequate protection for our intellectual property, it may adversely affect the value of our technology and devices and future revenue and operating income.
- Our ability to innovate or market our products may be impaired by the intellectual property rights of third parties.
- We may not be able to consummate future acquisitions or successfully integrate acquisitions into our business, which could result in unanticipated expenses and losses.
- Any due diligence by us in connection with an acquisition may not reveal all relevant considerations or liabilities of the target business, which could have a material adverse effect on our financial condition or results of operations.
- The success of our business is partially dependent on our ability to raise capital, and failure to raise the necessary capital may adversely affect our results of operations, financial condition and stock price.
- We have outstanding debt, and may incur other debt in the future, which could adversely affect our financial condition, liquidity and results of operations.
- Our business depends on our ability to attract and retain talented employees.
- We have a concentration of risk related to the accounts receivable from Medicare and failure to fully collect outstanding balances from this customer, or a combination of other customers, may adversely affect our results of operations.
- Our business may be impacted by political events, war, terrorism, public health issues, natural disasters and other business interruptions.
- New products and technological advances by our competitors may negatively affect our market share, commercial opportunities and results of operations.
- Our efforts to develop new products may not be successful or the new products may not provide the revenue we expect.
- We operate in an intensely competitive industry, and our failure to respond quickly to technological developments and incorporate new features into our products could harm our ability to compete.
- If we or our suppliers fail to achieve or maintain regulatory approval of manufacturing facilities, our growth could be limited and our business could be adversely affected.
- Our dependence on a limited number of suppliers may prevent us from delivering our devices on a timely basis.
- We could be subject to medical liability or product liability claims, which may not be covered by insurance and which would adversely affect our business and results of operations.
- Our products may in the future be subject to product recalls that could harm our reputation and product liability claims.
- We are reliant on the outsourcing of clinical research by pharmaceutical, clinical research and biotechnology companies.
- Future sales of our common stock may depress our stock price.
- Anti-takeover provisions in our charter documents and Delaware law might deter acquisition bids for us that our stockholders might consider favorable.
- Our future profitability is uncertain.
- We may not be able to realize our net operating loss carryforwards.
Management Discussion
- Total revenue for the three months ended September 30, 2020 increased 3.0% due to growth in Healthcare and Corporate and Other category revenue, partially offset by the decrease in Research revenue. The increase in Healthcare revenue was driven by growth in our recurring cardiac monitoring and extended wear Holter services, partially offset by lower mobile cardiac telemetry (“MCT”) patient revenue resulting from the impact of COVID-19 and negative payor mix. However, as the stay-at-home orders have continued to be lifted and medical professionals have adjusted their practices to the pandemic, we continue to see an increase in overall demand for our monitoring services since the low point in April. Research revenue declined due to study close outs coupled with the delay in new study starts, primarily due to COVID–19. Corporate and Other revenue increased due to growth of population health platform and services.